Drug Profile
Monoclonal antibody EC708
Alternative Names: DeImmunised antibody EC708; EC708Latest Information Update: 02 Jul 2002
Price :
$50
*
At a glance
- Originator Biovation
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 01 Nov 2000 Biovation has been acquired by Merck KGaA
- 13 Nov 1998 New profile
- 13 Nov 1998 Preclinical development for Colorectal cancer in United Kingdom (Unknown route)